

OK TO ENTER: /J.B./

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A drug delivery system comprising a contact lens having dispersed therein as nanoparticles an ophthalmic drug nanoencapsulated with an encapsulation material, wherein said encapsulation material is selected dependent upon ophthalmic drug characteristics wherein a hydrophobic encapsulation material is selected for a hydrophobic ophthalmic drug and a hydrophilic encapsulation material is selected for a hydrophilic ophthalmic drug; and wherein said ophthalmic drug is capable of diffusion into and migration through said contact lens and into the post-lens tear film when said contact lens is placed on the eye; wherein said diffusion results in extended or time-release delivery of said ophthalmic drug.
2. (Previously Presented) The drug delivery system of claim 1, each said nanoparticles having a particle size less than about 50 nm.
3. (Previously Presented) The drug delivery system of claim 2 wherein said nanoparticles are dispersed within said contact lens in an amount such that said contact lens remains optically transparent, wherein optically transparent is a degree of transparency equal to that of p-HEMA or other material employed as a contact lens and wherein said amount of nanoparticles is from about 1 to about 5%, by weight, based on the weight of the contact lens.
4. (Previously Presented) The drug delivery system of claim 1 wherein said contact lens comprises poly 2-hydroxyethylmethacrylate, and wherein the transmittance of visible light through said contact lens is at least 66%.
5. (Previously Presented) The drug delivery system of claim 1, wherein said hydrophilic encapsulation material is a liposome.